Clinical trials · California
Cancer clinical trials in California
We’re tracking 1,320 recruiting cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Arroyo Grande, CaliforniaAges Any age - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Duarte, CaliforniaAges 18 years+ - NCT04722341Recruiting
Time-limited eating for people with certain breast or rectal cancers
This study tests whether eating only within a shorter daily time window can improve cancer outcomes in people with specific breast or rectal cancers. It also looks at how this affects the body (such as metabolism) and who is most likely to benefit.
West Hollywood, CaliforniaAges 18 years+ - NCT05451004RecruitingPhase 3
SPECT-CT test to target neck radiation on one side
This study tests whether using a special scan (SPECT-CT) can guide radiation treatment to only the safer/needed side of the neck in people with a one-sided oropharyngeal cancer. It aims to keep cancer control while potentially reducing side effects from unnecessary radiation.
Corona, CaliforniaAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Duarte, CaliforniaAges 18 years+ - NCT05401110RecruitingPhase 1
Osimertinib plus antibody treatment for EGFR-mutated lung cancer
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
Beverly Hills, CaliforniaAges 18 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Encinitas, CaliforniaAges 18 years+ - NCT05204147RecruitingPhase 1
Radioactive antibody for CEA-making advanced cancers
This early-phase trial tests a radioactive antibody (Ac225-DOTA-M5A) that targets CEA, a protein found on many cancer cells. It's for people with advanced or metastatic cancers that produce CEA and who have no good standard treatment options left.
Duarte, CaliforniaAges 18 years+ - NCT05227326RecruitingPhase 1
A new drug for solid cancers that did not respond to usual care
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
Long Beach, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Palo Alto, CaliforniaAges 18 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Beverly Hills, CaliforniaAges 18 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Los Angeles, CaliforniaAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04706663Recruiting
Genomics-guided treatment for people with prostate cancer
This trial uses genetic test results from your prostate cancer to guide treatment choices. It may help find therapies that better match the specific gene changes in your cancer.
La Jolla, CaliforniaAges 18–120 - NCT04742608Recruiting
Liquid blood tests to diagnose thyroid nodules or cancer
This study tests whether a blood “liquid biopsy” can help diagnose thyroid cancer or hard-to-tell thyroid nodules without needing extra procedures. It may help confirm what’s going on before or around planned thyroid surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT04768426RecruitingPhase 2
Watching DNA in blood while taking capecitabine after breast cancer
This trial checks how a blood test that looks for cancer DNA (ctDNA) changes during and after you take capecitabine after early triple-negative breast cancer. It aims to see whether these blood test results can help monitor the chance of the cancer coming back.
Stanford, CaliforniaAges 18 years+ - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Irvine, CaliforniaAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Los Angeles, CaliforniaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+
Cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting cancer studies listed above.
- Cedars-Sinai Medical Center · 6 studies
- City of Hope · 6 studies
- UC San Diego Moores Cancer Center · 5 studies
- USC Norris Comprehensive Cancer Center · 5 studies
- Hoag Memorial Hospital Presbyterian · 3 studies
- Stanford University · 3 studies
- UCSF Medical Center · 3 studies
- City of Hope at Irvine Lennar · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in California?
- Yes. We're currently tracking 1,320 recruiting cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.